Allovir, Inc.

KLRS

Explore Our Financial Data > Companies > All US Companies > Allovir, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
KLRS
CIK0001754068
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address1100 WINTER STREET, WALTHAM, MA, 02451
Website allovir.com
Phone(617) 433-2605
CEODiana M. Brainard
Employees110

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-65.52 million
Net Income$-65.56 million
Net Income to Common$-65.56 million
EPS$-16.17
View All
Balance Sheet
Cash$100.96 million
Assets$103.09 million
Liabilities$39.22 million
Common Equity$63.87 million
Liabilities & Equity$103.09 million
View All
Cash Flow Statement
Net Income$-65.56 million
Cash From Operating Activities$-70.62 million
Cash From Investing Activities$95.00 million
Cash From Financing Activities$100.71 million
Change in Cash$125.08 million
View All
Calculations
NOPAT$-51.26 million
EBITDA$-71.09 million
Price to EarningsN/A
Price to Book$0.98
ROE-71.14%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clini

Article Link

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growthPALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted t

Article Link

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq

Article Link

Kalaris and AlloVir Announce Stockholder Approval of Merger

Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12,

Article Link

AlloVir and Kalaris enter merger to advance retinal disease therapies

The combined entity will operate as Kalaris Therapeutics, with approximately $100m in cash reserves.

Article Link